Data on the effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with mild COVID-19.

  1. Casellas, Aina 1
  2. Montero, Alejandro Fernández 2
  3. Matteo, Andrés Blanco-Di 2
  4. Belen Sadaba 2
  5. Chaccour, Carlos 1
  6. Dobaño, Carlota 1
  7. Iborra, Carlota Jordán 2
  8. Laso, Ester 2
  9. Hammann, Felix 3
  10. Torre, Francisco Carmona 2
  11. Reina, Gabriel 2
  12. Moncunill, Gemma 1
  13. Pineda, Iñigo 2
  14. Brew, Joe
  15. Pozo, José L. Del 2
  16. Yuste, José R. 2
  17. Mateos, Mariano Rodríguez 2
  18. Mary-Ann Richardson 1
  19. Alonso, Miriam Fernández 2
  20. Giráldez, Miriam 2
  21. Castillo, Paula Ruiz 1
  22. Rabinovich, Regina 1
  23. Schöning, Verena 3
  1. 1 Instituto de Salud Global de Barcelona
    info

    Instituto de Salud Global de Barcelona

    Barcelona, España

  2. 2 Clínica Universitaria de Navarra
    info

    Clínica Universitaria de Navarra

    Pamplona, España

    ROR https://ror.org/03phm3r45

  3. 3 University Hospital of Bern
    info

    University Hospital of Bern

    Berna, Suiza

    ROR https://ror.org/01q9sj412

Mostrar afiliaciones +

Editor: CORA.Repositori de Dades de Recerca

Año de publicación: 2022

Tipo: Dataset

DOI: 10.34810/DATA106 lock_openAcceso abierto editor

Resumen

The trial was conducted in the Pamplona metropolitan area (Navarra, Spain). Patients were enrolled between July 31, 2020 and September 11, 2020 and randomized in a 1:1 ratio to ivermectin (400 mcg/kg) single oral dose or placebo. Assessments on enrollment and at days 4, 7, 14, 21 and 28 post treatment included: general symptoms report, physical examination and adverse events. All patients were asked to complete a daily online diary of symptoms from day 1 to 28 post treatment. On enrollment, as well as on days 7 and 14 blood samples were obtained to assess full blood count, C reactive protein, procalcitonin, ferritin, creatinine phosphokinase, lactic dehydrogenase, troponin T, D dimer, IL-6, and renal function. Viral loads were calculated at enrollment and on days 4, 7, 14 and 21 post treatment based on a nasopharyngeal swab for SARS-CoV-2 PCR (for genes N and E). A semi-quantitative serology for IgG against SARS-CoV-2 was done on samples from all patients on day 21 post-treatment.